A Phase 2 interventional study of AZD1722 and Placebo in Hyperphosphatemia, sponsored by Ardelyx. Completed at 41 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-09-14.
Sponsored by Ardelyx · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing tenapanor in Hyperphosphatemia — none open to participants now, none under way, none of them phase 3. tenapanor · Hyperphosphatemia.
Among the 13 studies testing tenapanor in Hyperphosphatemia, this one is the 10th largest by enrollment, is the only one that started in 2014, is one of 4 in phase 2, and was the 1st registered.
173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.
Browse Hyperphosphatemia studies →None of the 13 studies testing tenapanor in Hyperphosphatemia is open now. The open studies under Hyperphosphatemia, anywhere →
tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →
Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 7 · Phase 4 2
First in 2014; this study’s year is marked. 1 started in 2014.
This study's enrollment of 162 is above the median of 101 across 143 interventional studies indexed under Hyperphosphatemia.
Median enrollment 172 across the 13 interventional studies. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 13 have an industry lead sponsor. The 2 most frequent:
Ardelyx is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Ardelyx has 6 studies filed under Hyperphosphatemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing tenapanor in Hyperphosphatemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Randomized. double blind, placebo controlled, parallel arms dose finding study with a 4 weeks treatment period
The study consists of a screening period of approximately 1 week, a wash out period of up to 3 weeks, where existing phosphate lowering medication is withheld, a 4-week treatment period and a follow-up period of up to 2 weeks, during which patients are put back on their pre washout phosphate lowering medication.
The wash out period will be either 1 week, 2 weeks or 3 weeks depending on the increase in s-phosphate levels.
There are 7 parallel treatment arms in the study with bid and od treatment regimens.
Laboratory efficacy endpoints and safety assessments will be evaluated at various times throughout the study.
The target population of the study is: male or female patients, above18 years of age with End Stage Renal Disease (ESRD) on chronic maintenance hemodialysis (HD) 3 times a week for a minimum of 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Clinical signs of hypovolemia at randomization
-
1 mg AZD1722 bid
Drug: AZD1722
3 mg AZD1722 bid
Drug: AZD1722
10 mg AZD1722 bid
Drug: AZD1722
30 mg AZD1722 bid
Drug: AZD1722
3 mg AZD1722 od
Drug: AZD1722
30 mg AZD1722 od
Drug: AZD1722
Placebo (double dummy technique)
Drug: Placebo
AZD1722, oral tablet
Placebo bid, double dummy technique
Change in Serum Phosphate Levels
Change in serum phosphate levels from the end of wash out (pre randomization value) to end of treatment
Time frame: End of wash out (pre randomization value) to end of treatment (Day 29)
Change From Baseline in Calcium x Phosphorus Product
Change from baseline (end of wash out) in calcium x phosphorus product
Time frame: End of wash out (pre randomization value) to end of treatment (Day 29)
| Milestone | 1 mg Bid | 3 mg Bid | 10 mg Bid | 30 mg Bid | 3 mg od | 30 mg od | Placebo |
|---|---|---|---|---|---|---|---|
| Started | 23 | 21 | 23 | 26 | 22 | 21 | 26 |
| Completed | 18 | 13 | 19 | 13 | 18 | 12 | 22 |
| Not completed | 5 | 8 | 4 | 13 | 4 | 9 | 4 |
| Withdrew: Adverse event | 5 | 4 | 3 | 10 | 2 | 8 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 1 | 1 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 3 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 1 | 1 | 0 |
Change in serum phosphate levels from the end of wash out (pre randomization value) to end of treatment
| mg/dL | 1 mg Bid | 3 mg Bid | 10 mg Bid | 30 mg Bid | 3 mg od | 30 mg od | Placebo |
|---|---|---|---|---|---|---|---|
| Change in Serum Phosphate Levels | -.47 ± 1.553 | -1.18 ± 1.391 | -1.7 ± 2.018 | -1.98 ± 2.007 | -.56 ± 1.763 | -1.11 ± 1.469 | -.54 ± 1.802 |
Change from baseline (end of wash out) in calcium x phosphorus product
| mg/dL * mg/dL | 1 mg Bid | 3 mg Bid | 10 mg Bid | 30 mg Bid | 3 mg od | 30 mg od | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Calcium x Phosphorus Product | -5.16 ± 9.75 | -12.02 ± 14.02 | -12.44 ± 15.94 | -16.6 ± 18.01 | -3.59 ± 18.59 | -11.02 ± 11.57 | -2.50 ± 13.67 |
Collected over Adverse events were collected for a total of 5 weeks; 4-weeks of treatment and 1 treatment-free week. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1 mg Bid | 1/23 (4.3%) | 2/23 (8.7%) | 6/23 (26.1%) |
| 3 mg Bid | 0/21 (0%) | 2/21 (9.5%) | 6/21 (28.6%) |
| 10 mg Bid | 0/23 (0%) | 3/23 (13%) | 11/23 (47.8%) |
| 30 mg Bid | 0/26 (0%) | 2/26 (7.7%) | 17/26 (65.4%) |
| 3 mg od | 0/22 (0%) | 1/22 (4.5%) | 4/22 (18.2%) |
| 30 mg od | 0/21 (0%) | 0/21 (0%) | 11/21 (52.4%) |
| Placebo | 0/26 (0%) | 4/26 (15.4%) | 3/26 (11.5%) |
| Event | 1 mg Bid | 3 mg Bid | 10 mg Bid | 30 mg Bid | 3 mg od | 30 mg od | Placebo |
|---|---|---|---|---|---|---|---|
| pneumoniaInfections and infestations | 0/23 | 1/21 | 0/23 | 0/26 | 0/22 | 0/21 | 1/26 |
| Head injuryInjury, poisoning and procedural complications | 0/23 | 1/21 | 0/23 | 0/26 | 0/22 | 0/21 | 0/26 |
| Lacunar infarctionNervous system disorders | 0/23 | 0/21 | 0/23 | 0/26 | 1/22 | 0/21 | 0/26 |
| Chest painCardiac disorders | 1/23 | 0/21 | 0/23 | 1/26 | 0/22 | 0/21 | 0/26 |
| Cardiac failureCardiac disorders | 1/23 | 0/21 | 0/23 | 0/26 | 0/22 | 0/21 | 0/26 |
| osteomyelitisInfections and infestations | 0/23 | 0/21 | 1/23 | 0/26 | 0/22 | 0/21 | 0/26 |
| Fluid overloadMetabolism and nutrition disorders | 0/23 | 0/21 | 1/23 | 0/26 | 0/22 | 0/21 | 0/26 |
| SyncopeNervous system disorders | 0/23 | 0/21 | 1/23 | 0/26 | 0/22 | 0/21 | 0/26 |
| Rectal prolapseGastrointestinal disorders | 0/23 | 0/21 | 0/23 | 1/26 | 0/22 | 0/21 | 0/26 |
| Deep vein thrombosisVascular disorders | 0/23 | 0/21 | 0/23 | 1/26 | 0/22 | 0/21 | 0/26 |
| Event | 1 mg Bid | 3 mg Bid | 10 mg Bid | 30 mg Bid | 3 mg od | 30 mg od | Placebo |
|---|---|---|---|---|---|---|---|
| DiarrheaGastrointestinal disorders | 6/23 | 6/21 | 11/23 | 17/26 | 4/22 | 11/21 | 3/26 |
| Age, Continuous(years) | 1 mg Bid | 3 mg Bid | 10 mg Bid | 30 mg Bid | 3 mg od | 30 mg od | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 57.9 ± 14.79 | 61.5 ± 11.21 | 62.7 ± 12.53 | 59.7 ± 12.96 | 57.6 ± 15.78 | 58.2 ± 15.75 | 56.1 ± 13.14 | 59.1 ± 14.1 |
| Sex: Female, Male(Participants) | 1 mg Bid | 3 mg Bid | 10 mg Bid | 30 mg Bid | 3 mg od | 30 mg od | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 16 | 15 | 15 | 17 | 12 | 13 | 16 | 104 |
| Male | 7 | 6 | 8 | 9 | 10 | 8 | 10 | 58 |
| Ethnicity (NIH/OMB)(Participants) | 1 mg Bid | 3 mg Bid | 10 mg Bid | 30 mg Bid | 3 mg od | 30 mg od | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 7 | 10 | 4 | 8 | 6 | 6 | 48 |
| Not Hispanic or Latino | 16 | 14 | 13 | 22 | 14 | 15 | 20 | 114 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 1 mg Bid | 3 mg Bid | 10 mg Bid | 30 mg Bid | 3 mg od | 30 mg od | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 8 |
| Asian | 1 | 0 | 3 | 1 | 1 | 0 | 3 | 9 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 2 | 8 | 3 | 9 | 6 | 3 | 4 | 35 |
| White | 17 | 12 | 16 | 15 | 13 | 16 | 17 | 106 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| serum phosphorus(mg/dL) | 1 mg Bid | 3 mg Bid | 10 mg Bid | 30 mg Bid | 3 mg od | 30 mg od | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 7.55 ± 1.003 | 7.92 ± 1.005 | 7.32 ± 1.063 | 7.76 ± 1.183 | 7.73 ± 1.276 | 7.61 ± 0.847 | 7.87 ± 1.488 | 7.68 ± 1.124 |
The record gives a start of Mar 2014, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2020, 5 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenapanor